The Pharma Letter has published an expert view by Ramji Vasudevan, Head of Life Sciences at Altimetrik, titled “AI-first is not a strategy. It’s how the next generation of pharmaceuticals will operate.”
In the article, Ramji explains why pharmaceutical companies must move beyond pilots and embrace AI-first operations as a foundation for growth. He highlights Altimetrik’s own journey including the creation of Alti AI Adoption Lab, an AI innovation engine that accelerates experiments across drug discovery, clinical development, manufacturing, supply chain intelligence, and commercial analytics. By reducing time-to-value for AI initiatives by over 30%, Alti AI Adoption Lab demonstrates how pharma can achieve faster, scalable results.
Ramji also stresses that the real shift is cultural, not just technological requiring leadership to integrate AI deeply into core processes while empowering employees to adopt new AI-driven capabilities. With agentic AI on the horizon, he calls on pharma leaders to take decisive action or risk being outpaced by AI-native competitors.
Launches PharmaOS as the Center’s first offering, taking clients from concept to validation in a week
Vikas Krishan, Chief Digital Business Officer and Head of UK and EMEA at Altimetrik, explains in The Fintech Times why rising AI usage does not guarantee better business outcomes. As organisations adopt agentic AI, he calls for clearer links between cost, value and ownership. He also argues that changes to EU AI Act timelines should […]
Altimetrik CEO Raj Sundaresan is featured in Newsweek, bringing our approach to AI, talent development and workplace culture to a global audience. Recognised among America’s Greatest Workplaces in Tech 2026, Altimetrik puts these commitments into practice through learning, experimentation and meaningful career opportunities. With more than 80% of our workforce having completed foundational AI training, […]
